All In Biotech

Drug Trial Radar · NCT05042128

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

158

Actual

Start

Apr 13, 2022

Primary completion

Jun 1, 2025

Study completion Oct 1, 2025

Sponsor

Sponsor type
Research network
Collaborators
University of Sydney
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the ASCEND clinical trial is to measure the effect of adding LSTA1 (certepetide), compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Cancer

Interventions

  • LSTA1Drug

    LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC

  • Gemcitabine InjectionDrug

    Chemotherapy drug provided as solution to be administered via IV infusion.

  • Nab paclitaxelDrug

    Chemotherapy drug provided as solution to be administered via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: From date of randomization to 18 months later, or death

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Border Medical Oncology

    Albury, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Monash Medical Centre

    Clayton, New South Wales, Australia

  • Lake Macquarie Private Hospital

    Gateshead, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Calvary Mater Newcastle

    Newcastle, New South Wales, Australia

  • Newcastle Private Hospital

    Newcastle, New South Wales, Australia

  • Prince of Wales Hospital

    Sydney, New South Wales, Australia

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Royal Brisbane and Womens Hospital

    Herston, Queensland, Australia

  • ICON Cancer Centre, Gold Coast University Hospital

    Southport, Queensland, Australia

  • Flinders Medical Centre

    Adelaide, South Australia, Australia

  • Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Launceston General Hospital

    Launceston, Tasmania, Australia

  • Northern Health

    Epping, Victoria, Australia

  • Warringal Private Hospital

    Heidelberg, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Frankston Hospital

    Melbourne, Victoria, Australia

  • Epworth Healthcare

    Richmond, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • St John of God

    Subiaco, Western Australia, Australia

  • Dunedin Hospital

    Dunedin, New Zealand

  • Waikato Hospital

    Hamilton, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.